Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Mar 28;4(2):9.
doi: 10.3390/vaccines4020009.

Vaccine Delivery Methods into the Future

Vasso Apostolopoulos  1
Affiliations
Editorial

Vaccine Delivery Methods into the Future

Vasso Apostolopoulos. Vaccines (Basel). .

Abstract

Several modes of vaccine delivery have been developed in the last 25 years, which induce strong immune responses in pre-clinical models and in human clinical trials. Some modes of delivery include, adjuvants (aluminum hydroxide, Ribi formulation, QS21), liposomes, nanoparticles, virus like particles, immunostimulatory complexes (ISCOMs), dendrimers, viral vectors, DNA delivery via gene gun, electroporation or Biojector 2000, cell penetrating peptides, dendritic cell receptor targeting, toll-like receptors, chemokine receptors and bacterial toxins. There is an enormous amount of information and vaccine delivery methods available for guiding vaccine and immunotherapeutics development against diseases.

Keywords: antigen delivery; immunotherapy; vaccine; vaccine delivery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Working conditions of Edward Jenner, “Jenner’s Hut” (left) used to inject people against smallpox, compared to working conditions today for developing new vaccine delivery methods (right).
See this image and copyright information in PMC

References

    1. Abdulhaqq S.A., Weiner D.B. DNA vaccines: Developing new strategies to enhance immune responses. Immunol. Res. 2008;42:219–232. doi: 10.1007/s12026-008-8076-3. - DOI - PubMed
    1. Kutzler M.A., Weiner D.B. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 2008;9:776–788. doi: 10.1038/nrg2432. - DOI - PMC - PubMed
    1. Pietersz G.A., Tang C.K., Apostolopoulos V. Structure and design of polycationic carriers for gene delivery. Mini Rev. Med. Chem. 2006;6:1285–1298. doi: 10.2174/138955706778992987. - DOI - PubMed
    1. Apostolopoulos V., Yu M., Corper A.L., Teyton L., Pietersz G.A., McKenzie I.F., Wilson I.A., Plebanski M. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: A new approach for vaccine design. J. Mol. Biol. 2002;318:1293–1305. doi: 10.1016/S0022-2836(02)00196-1. - DOI - PubMed
    1. Finnefrock A.C., Freed D.C., Tang A., Li F., He X., Wu C., Nahas D., Wang D., Fu T.M. Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus. Hum. Vaccines Immunother. 2016 doi: 10.1080/21645515.2016.1164376. - DOI - PMC - PubMed

Publication types

LinkOut - more resources